In addition, EGFR exon 20 insertions, Erb-B2 receptor tyrosine kinase 2 (ERBB2) mutations, neuregulin 1 (NRG1) fusions, KRAS proto-oncogene (KRAS) G12C, and tumor mutational burden (TMB) are evolving targeting/biomarkers and may eventually be included in the test panels, if possible [6,7]. Here, ERBB2 is linked to neoplasm.